Bahl & Gaynor Inc. Has $4.12 Million Stock Position in Kenvue Inc. (NYSE:KVUE)

Bahl & Gaynor Inc. lowered its stake in Kenvue Inc. (NYSE:KVUE) by 8.1% during the fourth quarter, Holdings Channel.com reports. The fund owned 192,806 shares of the company’s stock after selling 17,013 shares during the period. Bahl & Gaynor Inc.’s holdings in Kenvue were worth $4,116,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Grove Bank & Trust increased its position in shares of Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after acquiring an additional 947 shares during the last quarter. Geneos Wealth Management Inc. acquired a new stake in shares of Kenvue in the fourth quarter valued at about $29,000. SRS Capital Advisors Inc. increased its position in shares of Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after acquiring an additional 571 shares during the last quarter. Fortitude Family Office LLC increased its position in shares of Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after acquiring an additional 777 shares during the last quarter. Finally, Ashton Thomas Securities LLC acquired a new stake in shares of Kenvue in the third quarter valued at about $35,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Price Performance

Kenvue stock opened at $23.44 on Wednesday. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $44.79 billion, a price-to-earnings ratio of 44.22, a PEG ratio of 2.62 and a beta of 1.45. The stock’s 50 day moving average is $21.54 and its 200-day moving average is $22.30. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities research analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were paid a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.50%. The ex-dividend date was Wednesday, February 12th. Kenvue’s payout ratio is presently 154.72%.

Wall Street Analyst Weigh In

KVUE has been the topic of a number of recent research reports. UBS Group lowered their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. Citigroup lowered their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 15th. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and lowered their price target for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Piper Sandler boosted their price target on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. Finally, Barclays lowered their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Friday, January 17th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Kenvue presently has an average rating of “Hold” and an average target price of $23.33.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.